



Increase of number of shares and votes in Vicore Pharma

Gothenburg, January 31, 2020 – Vicore Pharma Holding AB (publ)'s ("Vicore Pharma") registered share capital and number of outstanding shares and votes have increased during the month of January 2020.

The number of shares and votes in Vicore Pharma in January 2020 increased through the exercising of warrants under a warrant program for key employees and key researchers in Vicore. The warrants were issued in January 2016. The total number of shares and votes has increased by 243,525.

As of today, the total number of registered and outstanding shares and votes of Vicore Pharma amounts to 50,418,239. Furthermore, the registered share capital amounts to SEK 25,209,119.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 31 January 2020 at 08:00 CET.

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis ("IPF") and systemic sclerosis ("SSc"). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an "IMiD"). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.